DFTX Definium Therapeutics, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1813814 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-100.8%
TTM EPS YoY-47.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-61.4%
ROA-51.5%
ROIC (approx.)-43.9%
Asset turnover—
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.04x
Current ratio15.53x
Interest coverage-51.91x
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-22.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $117.67M | $65.30M | $52.12M | $36.17M | $34.79M |
| SG&A expense | $48.64M | $38.62M | $41.74M | $30.16M | $59.06M |
| Operating income | -$166.31M | -$103.92M | -$93.87M | -$66.33M | -$93.85M |
| Interest expense | $5.48M | $2.28M | $920,000 | — | — |
| Pretax income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | -$94.19M |
| Income tax | $0 | — | — | — | -$1.16M |
| Net income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | -$93.04M |
| EPS (basic) | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 |
| EPS (diluted) | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 |
| Weighted avg. shares (diluted) | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M |
| Banking | |||||
| Net interest income | — | — | $4.66M | $1.50M | -$359,000 |
| Balance sheet | |||||
| Cash & equivalents | $257.84M | $273.74M | $99.70M | $142.14M | $133.54M |
| Short-term investments | $153.76M | $0 | — | — | — |
| Current assets | $419.32M | $281.62M | $103.87M | $146.06M | $137.22M |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| Intangibles | — | $0 | $527,000 | $3.69M | $6.87M |
| Total assets | $440.10M | $302.15M | $124.54M | $169.99M | $164.00M |
| Current liabilities | $66.70M | $38.85M | $32.25M | $17.89M | $10.41M |
| Long-term debt | $40.58M | $21.85M | $14.13M | — | — |
| Total debt | $40.58M | $21.85M | $14.13M | — | — |
| Total liabilities | $107.77M | $60.70M | $46.41M | $19.08M | $12.34M |
| Shareholders' equity | $332.33M | $241.45M | $78.13M | $150.92M | $151.66M |
| Net debt | -$217.26M | -$251.89M | -$85.58M | — | — |
| Shares outstanding | 98.78M | 75.10M | 41.10M | 37.98M | 28.13M |
| Cash flow statement | |||||
| Operating cash flow | -$131.56M | -$79.13M | -$64.36M | -$50.14M | -$45.82M |
| Investing cash flow | -$151.61M | $0 | — | — | -$297,000 |
| Financing cash flow | $267.27M | $253.20M | $21.85M | $59.05M | $98.82M |
| Stock-based compensation | $20.10M | $16.91M | $15.18M | $13.71M | $42.72M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.